Body mass index predicts the incidence of radiation pneumonitis in breast cancer patients.
Publication/Presentation Date
1-1-2005
Abstract
In patients receiving breast radiotherapy, the risk of radiation pneumonitis has been associated with the volume of irradiated lung, and concomitant methotrexate, paclitaxel, and tamoxifen therapy. Many of the studies of radiation pneumonitis are based on estimates of pulmonary risk using central lung distance that is calculated using two-dimensional techniques. With the treatment of internal mammary nodes and three-dimensional treatment planning for breast cancer becoming increasingly more common, there is a need to further consider the impact of dose-volume metrics in assessing radiation pneumonitis risk. We herein present a case control study assessing the impact of clinical and dose-volume metrics on the development of radiation pneumonitis in patients receiving sequential chemotherapy and local-regional radiotherapy.
Volume
11
Issue
5
First Page
390
Last Page
398
ISSN
1528-9117
Published In/Presented At
Allen, A. M., Prosnitz, R. G., Ten Haken, R. K., Normolle, D. P., Yu, X., Zhou, S. M., Marsh, R., Marks, L. B., & Pierce, L. J. (2005). Body mass index predicts the incidence of radiation pneumonitis in breast cancer patients. Cancer journal (Sudbury, Mass.), 11(5), 390–398. https://doi.org/10.1097/00130404-200509000-00006
Disciplines
Medicine and Health Sciences | Oncology
PubMedID
16267908
Department(s)
Department of Radiation Oncology
Document Type
Article